We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Calithera Biosciences has achieved pharmacokinetic and pharmacodynamic goals for CB-1158 under its agreement with Incyte Corp., triggering a $12 million payment from Incyte.